Chimpanzee adenovirus can be used to manufacture the vaccine

Recently, a study published in Sci Transl Med magazine "Novel Adenovirus-Based Vaccines Induce Broad and Sustained T-Cell Responses to of HCV in Man," disclosure of the chimpanzee adenovirus can be used to manufacture the vaccine.

The results suggest that the chimpanzee carrier developed vaccines can trigger immune protection of the hepatitis C; caused by hepatitis C virus is expected to result in 100 million 70 million infections worldwide; is currently no vaccine for the disease. The human adenovirus is often used as a carrier of genes into human cells to deliver the vaccine or gene therapy. Vaccine encoding a particular pathogen antigen gene is packaged into the virus. Once these antigens are released into the cells within, they will trigger a protective immune response. However, recent studies have shown that the human adenovirus may not be the best vaccine vector, because many populations have come into contact with these viruses. This pre-existing immunity to the virus to stimulate some kind of new immune responses have been cleared before.

Taking into account the likelihood of most people from the chimpanzee, where microbial infection to be much smaller, so the researchers turned to consider the chimpanzee adenovirus as a potential vaccine vector. In one trial, Stefano Colloca and colleagues found a new set of chimpanzee adenovirus, and designed a screening strategy to their immune strength in mice (ie, to test their effectiveness as a vaccine vector) sort. The team proved that the chimpanzee adenovirus better than most of the human adenovirus effect. In an independent clinical trial, Eleanor Barnes and his colleagues in some drawn from the the Colloca research chimpanzees carrier to a small group of healthy volunteers injected with a possible hepatitis C vaccine. The chimpanzee virus vectors (with some rare human adenovirus vector) triggered the virus-specific immune response; it appears to be safe and well tolerated. During a more careful observation, the research team to see, from the vaccine for hepatitis C antigen activated memory T cells in the body of the test participants. Once exposed to a particular pathogen, T cells can help the body recognize and fight off future invaders. A "view section" discusses these findings and their significance on reducing persistent hepatitis C infection rates.